论文部分内容阅读
目的观察非小细胞肺癌患者外周血淋巴细胞亚群CD3+CD4+和CD3+CD8+及其表面受体NKG2D、NKG2A的表达水平,分析其表达水平与肺癌肿瘤免疫逃逸的相关性。方法采集34例肺癌患者外周血,按照TNM分期分为早期组(Ⅰ期和Ⅱ期)和晚期组(Ⅲ期、Ⅳ期),用流式细胞仪检测外周血,分析淋巴细胞亚群CD3+CD4+和CD3+CD8+及其表面受体NKG2D、NKG2A的表达及相关性。结果晚期组CD3+CD4+的表达水平较早期组降低,而CD3+CD8+的表达水平升高(P<0.05);晚期组肺癌患者CD3+CD4+NKG2D表达率(6.69±3.58%)高于早期组的表达率(2.38±1.13%),CD3+CD4+NKG2A表达率(2.28±0.88%)低于早期组的表达率(5.46±2.09%)(P<0.01);晚期组肺癌患者CD3+CD8+NKG2D表达率(90.57±2.49%)低于早期组的表达率(93.51±3.19%),CD3+CD8+NKG2A表达率(12.32±4.24%)高于早期组的表达率(7.15±3.30%)(P<0.01)。结论非小细胞肺癌病理分期间淋巴细胞亚群CD3+CD4+和CD3+CD8+表达水平的改变,NKG2D、NKG2A在CD3+CD4+和CD3+CD8+表面的表达失衡,可能是肿瘤免疫逃逸的机制之一。
Objective To observe the expression levels of CD3 + CD4 +, CD3 + CD8 + and NKG2D, NKG2A and NKG2A in peripheral blood lymphocyte subsets in patients with non-small cell lung cancer (NSCLC) and to analyze their correlation with tumor immune escape. Methods Peripheral blood samples of 34 patients with lung cancer were collected and divided into early stage (stage Ⅰ and stage Ⅱ) and advanced stage (stage Ⅲ, stage Ⅳ) according to TNM stage. Peripheral blood was analyzed by flow cytometry and lymphocyte subsets CD3 + CD4 + and CD3 + CD8 + and its surface receptors NKG2D, NKG2A expression and correlation. Results The expression of CD3 + CD4 + in the advanced stage was lower than that in the early stage, but the expression of CD3 + CD8 + was increased (P <0.05). The expression of CD3 + CD4 + NKG2D in the advanced stage was 6.69 ± 3.58% (2.38 ± 1.13%) and CD3 + CD4 + NKG2A (2.28 ± 0.88%) were lower than those in early stage (5.46 ± 2.09%, P <0.01) The expression rate of NKG2D was lower than that of the early stage (93.51 ± 3.19%), the expression of CD3 + CD8 + NKG2A was significantly higher than that of the early stage (90.57 ± 2.49%, 12.32 ± 4.24%, 7.15 ± 3.30% P <0.01). Conclusions The expression of CD3 + CD4 + and CD3 + CD8 + in lymphocyte subsets during pathologic stage of non-small cell lung cancer (NSCLC) is different. The expression of NKG2D and NKG2A on the surface of CD3 + CD4 + and CD3 + CD8 + may be one of the mechanisms of tumor immune escape.